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Influence of -Lactam Infusion Strategy
on Acute Kidney Injury
Sarah E. Cotner,a W. Cliff Rutter,a,b Donna R. Burgess,a,b Katie L. Wallace,a,b
Craig A. Martin,a,b David S. Burgessb
University of Kentucky HealthCare, Lexington, Kentucky, USAa; University of Kentucky, College of Pharmacy,
Lexington, Kentucky, USAb
ABSTRACT Limited literature is available assessing nephrotoxicity with prolonged
-lactam infusions. This study compared the incidence of acute kidney injury (AKI)
associated with a prolonged -lactam infusion or an intermittent infusion. This was a
retrospective, matched-cohort study at an academic medical center from July 2006
to September 2015. Adult patients who received piperacillin-tazobactam (TZP),
cefepime (FEP), or meropenem (MEM) for at least 48 h were evaluated. Patients were
excluded for preexisting renal dysfunction or pregnancy. The primary outcome was
difference in incidence of AKI evaluated using the RIFLE (risk, injury, failure, loss, and
end-stage) criteria. Patients in the intermittent group were matched 3:1 to patients
in the prolonged-infusion group based on the following: -lactam agent, age, gen-
der, Charlson comorbidity index, baseline creatinine clearance, hypotension, receipt
of vancomycin, and treatment in an intensive care unit. A total of 2,390 patients
were included in the matched analysis, with 1,700 receiving intermittent infusions
and 690 receiving prolonged infusion. The incidence of AKI was similar in the
prolonged-infusion group to that in the intermittent-infusion group (21.6% versus
18.6%; P  0.1). After multivariate regression, prolonged infusion was not associated
with increased odds of AKI (odds ratio [OR], 1.07; 95% confidence interval [95% CI],
0.83 to 1.39). Independent predictors of AKI included TZP therapy, concomitant
nephrotoxins, hypotension, and heart failure. Although AKIs were numerically more
common in patients receiving prolonged -lactam infusions than those receiving in-
termittent infusions, prolonged infusion was not an independent risk factor for AKI.
KEYWORDS acute kidney injury, -lactams, extended infusion
The -Lactam antibiotics are an antimicrobial class with extensive clinical utility andare the mainstay of treatment in many Gram-positive and Gram-negative infections.
These agents are bactericidal through inhibition of bacterial cell wall synthesis and exhibit
time-dependent killing of microorganisms (1). Thus, the activity of -lactam antibiotics
depends on the free drug concentration time above the MIC of the targeted organism.
-Lactams are typically dosed intermittently and infused over 30 to 60 min. Prolonged
-lactam infusions are promoted as a strategy to optimize the percentage of the dosing
interval that the concentration of free drug remains above the MIC. Enhancement of
-lactam pharmacodynamics is particularly useful in critically ill patients with altered
pharmacokinetics and those who are at risk for resistant pathogens. Prolonged -lactam
infusions are associated with decreased mortality in patients diagnosed with pneumonia, as
well as invasive Pseudomonas aeruginosa infections (2, 3).
While nephrotoxicity is a known adverse effect of -lactam antibiotics, there is a low
reported incidence of nephrotoxicity associated with traditional intermittent dosing.
Mechanisms of nephrotoxicity reported with beta-lactams include primarily acute
interstitial nephritis (AIN) and glomerulonephritis, although acute tubular necrosis
(ATN) has been noted (4, 5). The prolonged-infusion literature available primarily
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focuses on efficacy rather than safety. Thus, there is limited information available
regarding nephrotoxicity with prolonged infusion; the -lactam evaluated in existing
prolonged-infusion literature is piperacillin-tazobactam (TZP). Lau and colleagues re-
ported drug-related adverse events in their evaluation of TZP administered via a
continuous infusion over 24 h versus intermittent infusion given every 6 h (6). Renal
failure was noted as a treatment-related adverse event in one patient treated with TZP
continuous infusion. McCormick et al. completed a retrospective study of 200 patients
and did not find a difference in acute kidney injuries (AKIs) between patients receiving
intermittent TZP infusions versus those receiving extended infusions (11% versus 9%;
P  0.637) (7). The literature to date suggests similar rates of nephrotoxicity in patients
receiving TZP and vancomycin (VAN) combination therapy, regardless of TZP infusion
strategy (8, 9). No previous studies have reported the impact of prolonged infusions on
AKI with -lactams other than TZP. Therefore, this study was formulated to evaluate the
incidence of AKIs based on TZP, cefepime (FEP), or meropenem (MEM) infusion strategy.
RESULTS
In total, 2,390 patients of the 18,313 evaluated met criteria to be included in our
matched analysis (Fig. 1), with 1,700 receiving intermittent infusions and 690 receiving
prolonged infusions.
The baseline characteristics of the matched cohort are displayed in Table 1. The
majority of baseline factors were well balanced between the prolonged-infusion and
intermittent-infusion groups, with the exception of exposure to aminoglycosides,
calcineurin inhibitors, intravenous (i.v.) contrast dye, loop diuretics, and vasopressors.
TZP was the most common -lactam utilized, with 37.0% of patients in the prolonged-
infusion group and 46.4% in the intermittent-infusion group receiving this antimicro-
bial. FEP was administered in the prolonged-infusion group to 31.0% of patients and
36.6% in the intermittent-infusion group. More patients in the prolonged-infusion
group received MEM (32.0% versus 16.9%; P  0.0001). Length of hospital stay was
significantly longer in the prolonged-infusion cohort (median of 12 days [range, 7 to 21
days] versus 10 days [5 to 18 days]; P  0.0001).
AKI incidences were similar between the prolonged- and intermittent-infusion
FIG 1 Patient selection diagram.
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cohorts (21.6% versus 18.6%; P  0.104), with no difference when stratified by RIFLE
(risk, injury, failure, loss, and end-stage) criteria (Table 2). AKIs were more common
among patients who received TZP (24.9%) compared to those receiving FEP or MEM
(15.9% and 14.1%, respectively; P  0.00001). After multiple regression, prolonged
infusion was not associated with increased odds of AKI (OR, 1.07; 95% confidence
interval [CI], 0.83 to 1.39). Several independent predictors of AKI were identified in the
analysis (Table 3). Concomitant nephrotoxins associated with increased risk of AKI
included aminoglycosides, amphotericin B, calcineurin inhibitors, loop diuretics, van-
comycin, and vasopressors. Patients receiving TZP had 1.95 times the odds of AKI (95%
TABLE 1 Baseline patient characteristics of matched cohort
Variablea
Result for infusion strategyb
P value
Prolonged
(n  690)
Intermittent
(n  1,700)
Age, mean (SD) yr 53.47 (17.1) 53.48 (16.9) 0.982
Male, no. (%) 427 (61.9) 1,028 (60.5) 0.551
Caucasian, no. (%) 631 (91.4) 1,562 (91.9) 0.789
Charlson comorbidity score, median (IQR) 3 (1–5) 3 (1–6) 0.518
Baseline CLCR, no. (%) 0.908
30–59 ml/min 129 (18.7) 331 (19.5)
60–89 ml/min 193 (28.0) 469 (27.6)
90 ml/min 368 (53.3) 900 (52.9)
ICU admission, no. (%) 189 (27.4) 431 (25.3) 0.328
Comorbidities, no. (%)
Diabetes mellitus 159 (23.0) 451 (26.5) 0.0855
Heart failure 118 (17.1) 241 (14.2) 0.08
Hypertension 384 (55.6) 905 (53.2) 0.303
Hypotension 428 (62.0) 1,002 (58.9) 0.177
-Lactam received, no. (%) 0.0001
Piperacillin-tazobactam 255 (37.0) 789 (46.4)
Cefepime 214 (31.0) 623 (36.6)
Meropenem 221 (32.0) 288 (16.9)
Concomitant nephrotoxins, no. (%)
Aminoglycoside 154 (22.3) 226 (13.3) 0.0001
Amphotericin B 13 (1.9) 37 (2.2) 0.768
ACE inhibitor 118 (17.1) 313 (18.4) 0.486
ARB 24 (3.5) 57 (3.3) 0.977
Calcineurin inhibitors 91 (13.2) 165 (9.7) 0.0154
i.v. contrast dye 271 (39.3) 553 (32.5) 0.0019
Loop diuretics 134 (19.4) 233 (13.7) 0.0006
NSAIDs 33 (4.8) 65 (3.8) 0.338
Vancomycin 533 (77.2) 1,327 (78.1) 0.705
Vasopressors 136 (19.7) 236 (13.9) 0.0005
aAbbreviations: IQR, interquartile range; CLCR, creatinine clearance; ACE, angiotensin-converting enzyme; ARB,
angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs.
bThe values shown represent the number (percentage) of patients unless otherwise indicated.
TABLE 2 Incidence of nephrotoxicity by infusion strategy
Variable
Result for infusion strategya
P valueProlonged (n  690) Intermittent (n  1,700)
AKI incidence, no. (%) 149 (21.6) 316 (18.6) 0.104
RIFLE criteria, no. (%)
Risk 86 (12.5) 186 (10.9)
Injury 39 (5.7) 74 (4.4)
Failure 24 (3.5) 56 (3.3)
aThe values shown represent the number (percentage) of patients.
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CI, 1.50 to 2.52) compared to those receiving FEP. Patients experiencing hypotension
had 1.43 times the odds of AKI (95% CI, 1.10 to 1.85). Heart failure at baseline was
associated with a 1.78 multiplicative increase in AKI odds (95% CI, 1.31 to 2.43).
DISCUSSION
In this single-center, retrospective matched-cohort study, we compared rates of
nephrotoxicity in patients who received prolonged infusion of -lactams versus those
with intermittent infusion. The incidence of AKI according to RIFLE criteria was 21.6%
with a prolonged-infusion strategy compared to 18.6% with an intermittent-infusion
strategy. Our observed nephrotoxicity rates were higher than the 9 to 11% reported by
McCormick et al. (7). This variance may be explained by differences in patient popula-
tions and AKI definition; while we defined AKI with RIFLE criteria, McCormick and
colleagues defined acute renal injury by an increase in serum creatinine of 0.5 mg/dl
within 24 h or a serum creatinine level of 2 times the patient’s baseline value.
Although the prolonged-infusion group had a numerically higher incidence of
TABLE 3 Multivariate regression results postmatchinga
Covariate
Bivariable regression Multivariable regression
OR CI P value aOR CI P value
Treatment group
Intermittent infusion (reference)
Prolonged infusion 1.21 0.97–1.50 0.093 1.07 0.83–1.39 0.584
Age group
18–44 yr (reference)
45–64 yr 1.21 0.95–1.55 0.12 1.11 0.83–1.48 0.474
65–79 yr 1.19 0.89–1.58 0.25 1.23 0.85–1.78 0.266
80 yr 0.80 0.49–1.28 0.376 1.10 0.61–2.00 0.745
Male 1.06 0.86–1.30 0.603
Caucasian 0.78 0.55–1.11 0.15 0.70 0.47–1.03 0.069
Charlson comorbidity score 1.02 1.00–1.05 0.099 1.00 0.97–1.04 0.856
Baseline CLCR of:
30–59 ml/min (reference)
60–89 ml/min 0.86 0.63–1.19 0.362 1.13 0.78–1.65 0.51
90 ml/min 1.33 1.02–1.76 0.04 2.42 1.67–3.50 0.001
Comorbidities
Diabetes 1.09 0.87–1.37 0.454
Heart failure 2.74 2.14–3.50 0.001 1.78 1.31–2.43 0.001
ICU admission 1.35 1.08–1.68 0.009 0.99 0.75–1.29 0.918
Hypotension 2.17 1.73–2.72 0.001 1.43 1.10–1.85 0.007
Hypertension 1.13 0.92–1.38 0.245
-Lactam
Cefepime (reference)
Meropenem 0.87 0.64–1.19 0.388 1.04 0.73–1.48 0.831
Piperacillin-tazobactam 1.76 1.39–2.22 0.001 1.95 1.50–2.52 0.001
Concomitant nephrotoxins
Aminoglycoside 2.41 1.88–3.07 0.001 1.71 1.29–2.27 0.001
Amphotericin B 2.84 1.57–5.01 0.001 2.13 1.03–4.43 0.042
ACE inhibitor 1.23 0.95–1.59 0.103 1.04 0.76–1.41 0.825
ARB 0.94 0.51–1.61 0.828 0.97 0.50–1.88 0.935
i.v. contrast dye 0.79 0.55–1.11 0.193 0.84 0.57–1.24 0.386
Calcineurin inhibitor 2.19 1.40–3.34 0.001 2.13 1.27–3.57 0.004
Loop diuretic 3.75 3.05–4.64 0.001 2.74 2.13–3.53 0.001
NSAIDs 0.80 0.59–1.07 0.137 0.70 0.50–0.99 0.041
Vancomycin 2.39 1.79–3.24 0.001 1.60 1.16–2.21 0.004
Vasopressor 3.34 2.62–4.24 0.001 1.98 1.45–2.72 0.001
aOR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; CLCR, creatinine clearance; ICU, intensive
care unit; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal
anti-inflammatory drugs.
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AKI than the intermittent-infusion group, multiple regression analysis revealed that
prolonged infusion was not independently associated with an increased risk of AKI.
Many of the variables that were independent risk factors of AKI in multiple regres-
sion analysis are anticipated, including administration of concomitant nephrotoxins,
hypotension, and receipt of TZP. Recent literature continues to suggest that TZP is
associated with a higher incidence of AKI than other intravenous -lactams when used
concomitantly with VAN (10, 11). Burgess and Drew reported that patients receiving
VAN combined with TZP were more likely to develop nephrotoxicity than patients who
received VAN alone (8.1% versus 16.3%; P  0.041) (10). In a study by Gomes and
colleagues, the incidence of AKI in patients receiving TZP and VAN was significantly
higher than that in patients receiving FEP and VAN (36.4% versus 10.9%; P  0.003) in
the matched analysis, and the investigators concluded that the combination of TZP and
VAN was an independent predictor of AKI (11). The concern for AKI induced with use
of TZP and VAN combination therapy raised a new clinical question— does the infusion
strategy of TZP affect the incidence of AKI when used concomitantly with VAN?
Documented nephrotoxicity rates in patients receiving TZP and vancomycin (VAN)
combination therapy are similar, regardless of TZP infusion strategy (8, 9). Results of a
study including 320 patients performed by Karino and colleagues suggest comparable
rates of AKI (32.5% versus 33.1%; P  1.0) in the prolonged- and intermittent-infusion
groups, respectively (8). Mousavi et al. had analogous findings in their study of 280
patients receiving combination TZP and VAN; the rates of nephrotoxicity did not differ
based on TZP infusion strategy (prolonged infusion, 17.9%, versus intermittent, 17.1%;
P  0.99) (9). The TZP nephrotoxicity rate in our study is similar to what has been
reported in the literature to date; however, unlike previous studies, not all patients
received vancomycin in combination with a -lactam in our analysis (77.2% in the
prolonged-infusion group versus 78.1% in the intermittent-infusion group). Addition-
ally, no previous studies have reported the impact of prolonged infusion on AKI with
-lactams other than TZP.
This study had several limitations, specifically the single-center, retrospective design.
An attempt to reduce bias and control for confounders was made through propensity
score matching and multiple logistic regression analysis. During the study period, there
was no protocol in place at our institution for use of extended-infusion -lactams. Due
to the retrospective nature of the study, evaluation of nursing compliance with the
prolonged-infusion order was not possible. Additionally, we acknowledge that the
potentials for nephrotoxicity were assumed to be equal among the concomitant
nephrotoxins analyzed. Exclusion of patients with a preexisting need for renal replace-
ment and creatinine clearance (CLCR) of 30 ml/min will limit the generalizability of our
results. Despite these limitations, this study currently provides the largest set of data
available assessing nephrotoxicity of prolonged-infusion -lactams.
In conclusion, prolonged infusion was not independently associated with increased
AKI risk compared to intermittent infusion. The results of this large retrospective study
lessen any concern that the use of prolonged infusion will cause increased incidence of
AKI and suggest it is safe for clinicians to prolong -lactam infusions to optimize
efficacy of treatment in their patients.
MATERIALS AND METHODS
Study design and setting. This retrospective matched-cohort study was conducted at University
of Kentucky HealthCare (UKHC) in Lexington, KY, which is comprised of two hospitals, the Albert B.
Chandler Medical Center and Good Samaritan Hospital. The study was approved by the investiga-
tional review board with a waiver of consent. Adult patients admitted from July 2006 to September
2015 who received TZP, FEP, or MEM for at least 48 h were evaluated. Patients were excluded for
preexisting renal dysfunction, cystic fibrosis, or pregnancy. Preexisting renal dysfunction was defined
as the need for renal replacement therapy or creatinine clearance (CLCR) of 30 ml/min at
presentation.
Data source and collection. Clinical data were extracted from the University of Kentucky Center for
Clinical and Translational Science Enterprise Data Trust (EDT). Data stored in the EDT include demo-
graphics, financial classification (Medicare, Medicaid, private insurance), medical diagnoses (International
Classification of Diseases 9 [ICD-9]), medical procedures (Current Procedural Terminology [CPT] codes),
laboratory results, vital signs, and visit details (length of stay, medical providers, etc.).
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Data collected included demographics, hospital visit data (length of stay, admitting and primary
diagnosis codes), laboratory values and vital signs obtained throughout admission, immunosuppression
status, receipt of concomitant nephrotoxins (listed in Table 1), severity of underlying comorbidity as
defined by the Charlson comorbidity index (12), and mortality information. Baseline creatinine
clearance was calculated with the adjusted Cockcroft-Gault equation from the first documented
serum creatinine level measured during admission (13). Concomitant nephrotoxins were defined as
receipt of at least 1 dose of a nephrotoxic agent during or within 24 h of treatment with -lactams.
Hypotension was defined as diagnosis of hypotension by ICD-9 codes, mean arterial pressure of 60
mm Hg, or receipt of vasopressors during or within 24 h of treatment (14). Antibiotic information
obtained included dosing regimen and days of antibiotic therapy, defined as receipt of at least one
dose of antibiotic per day.
Study outcome. The primary objective was to evaluate the incidence of AKI in patients receiving
prolonged infusion -lactam therapy compared to intermittent -lactam therapy defined by the RIFLE
(risk, injury, failure, loss, and end-stage) criteria (15). Prolonged infusion in this study includes both
extended infusions and infusions administered continuously over 24 h. -Lactam infusion strategy was
determined by the individual prescriber. Glomerular filtration rate (GFR) was estimated using the
maximum serum creatinine level between 48 h of initiation of the -lactam regimen through 7 days after
the last dose of antibiotics. The GFR estimation for use in the RIFLE criteria was completed via the
adjusted Cockcroft-Gault equation (13).
Patient matching. Propensity score matching was utilized to reduce potential bias and mimic
randomization. Patients in the intermittent group were matched 3:1 to patients in the prolonged-
infusion group based on the logistic regression model with the following variables included: -lactam
agent, age (as a categorical variable: 18 to 44, 45 to 64, 65 to 79, or 80 years of age), gender, Charlson
comorbidity index, baseline creatinine clearance, hypotension, receipt of vancomycin, and treatment in
the intensive care unit. A greedy, nearest-neighbor matching algorithm with a caliper of 0.2 was utilized
to ensure adequate matches.
Statistical analysis. Descriptive statistics were performed for the study population. Baseline char-
acteristics for each group were compared using a 2-tailed Student’s t test or Wilcoxon rank sum test for
continuous variables and chi-square or Fisher’s exact test for categorical variables. Following propensity
score matching, bivariable logistic regression models were generated to describe relationships between
the variables and outcomes. The final multiple regression model was created using covariates associated
with AKI from the bivariable models at a P value of 0.2. Significance was defined at an  of 0.05.
Goodness of fit of the multivariate logistic regression was evaluated with the standardized Hosmer-
Lemeshow test (16).
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